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Research
Bisphenol AF (also referred to as hexafluoro- 
bisphenol A) is a homolog of bisphenol A 
(BPA) (Figure 1). Bisphenol AF has a sym-
metrical chemical structure of HO–C6H4–
C(CF3)2–C6H4–OH and is designated as 
1,1,1,3,3,3-hexafluoro-2,2-bis(4-hydroxy-
phenyl)propane by IUPAC (International 
Union of Pure and Applied Chemistry) 
nomen  clature. Bisphenol AF–containing poly-
mers such as polycarbonate copolymers, poly-
imides, polyamides, and polyesters are used 
in high-temperature composites, electronic 
materials, and gas-permeable membranes. 
Bisphenol AF is also used in many other spe-
cialty polymer applications, including plastic 
optical fibers and waveguides. Although indus-
trial production of bisphenol AF seems to be 
increasing considerably, no data are available 
on annual production or concentrations of   
bisphenol AF in environmental substrates.
In 2008, the U.S. National Institute of 
Environmental Health Sciences nominated 
bisphenol AF for comprehensive toxicological 
characterization based on the lack of adequate 
toxicity data [National Toxicology Program 
(NTP) 2008a]. In this nomination report, 
the NTP noted concern regarding potential 
exposure of the general population to bis-
phenol AF. Structural dissimilarities between 
bisphenol AF and BPA are determined by the 
presence of a trifluoro  methyl (CF3) or methyl 
(CH3) group, respectively. The potential tox-
icity of bisphenol AF is of concern in part 
because its CF3 group is much more electro-
negative (and potentially reactive) than is the 
CH3 group of BPA.
Various “low-dose effects” of BPA have 
recently been reported in vivo for reproduc-
tive organ tissues in mice and rats. For exam-
ple, in utero exposures to very low levels of 
BPA have been shown to increase the size and 
weight of the fetal mouse prostate (Gupta 
2000; Nagel et al. 1997), and low-dose expo-
sures have also been reported to decrease daily 
sperm production and fertility in male mice 
(Gupta 2000; vom Saal et al. 1998). Many 
lines of evidence have recently indicated that 
low doses of BPA affect the central nervous 
system as well (vom Saal and Welshons 2005; 
Welshons et al. 2003, 2006). All of these low-
dose effects of BPA have been attributed to 
effects on steroid hormone receptors such as 
estrogen receptor (ER) and androgen receptor 
(AR) (Welshons et al. 2003; Xu et al. 2005). 
In the report by the NTP (2008b) on the 
potential for BPA exposure to affect human 
reproduction or development, “some concern”   
was indicated as the level of concern for 
potential effects on the brain, behavior, and 
the prostate gland. 
BPA exhibits extremely weak binding 
activity for ER and AR. Based on the idea that 
BPA may interact with nuclear receptors (NRs) 
other than ER and AR, we screened a series 
of NRs and eventually discovered estrogen-
related receptor γ (ERRγ) as the BPA target 
receptor (Takayanagi et al. 2006). BPA binds 
to ERRγ very strongly [dissociation constant 
(Kd) = 5.5 nM] with high constitutive basal 
activity (Liu et al. 2007; Okada et al. 2008; 
Takayanagi et al. 2006). Strong binding of 
BPA to ERRγ was further demonstrated by 
direct X-ray crystallographic analysis of this 
complex (Matsushima et al. 2007, 2008). 
Moreover, using real-time PCR (polymerase 
chain reaction), we recently demonstrated 
that human ERRγ mRNA is expressed abun-
dantly in the placenta, prostate, and fetal brain 
(Takeda et al. 2009).
Our efforts to explore the target recep-
tor of BPA suggested that it is essential to 
examine endocrine chemicals for inter  actions 
with all 48 human NRs. We previously 
reported that bisphenol AF binds to ERα 
more strongly than does BPA, and that the 
receptor selectivity of bisphenol AF is seven 
times higher for ERα than for ERRγ (Okada 
et al. 2008). There are two subtypes of estro-
gen receptors, ERα and ERβ, with distinctly 
different physio  logical distributions and func-
tions. Because effects of a number of chemi-
cals have been reported to differ between ERα 
and ERβ (Harris et al. 2003; Manas et al. 
2004), it is important to examine the effects 
of bisphenol AF on both ERs. In the present 
study, we evaluated the binding activity and 
functional biological activity of bisphenol AF 
for ERβ and found that bisphenol AF is a 
potent ligand that functions as an antagonist 
on ERβ.
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Ba c k g r o u n d: Bisphenol AF has been acknowledged to be useful for the production of CF3-
containing polymers with improved chemical, thermal, and mechanical properties. Because of the 
lack of adequate toxicity data, bisphenol AF has been nominated for comprehensive toxicological 
characterization.
oBjectives: We aimed to determine the relative preference of bisphenol AF for the human nuclear 
estrogenic receptors ERα and ERβ and the bisphenol A–specific estrogen-related receptor ERRγ, 
and to clarify structural characteristics of receptors that influence bisphenol AF binding.
Me t h o d s : We examined receptor-binding activities of bisphenol AF relative to [3H]17β-estradiol 
(for ERα and ERβ) and [3H]bisphenol A (for ERRγ). Functional luciferase reporter gene assays 
were performed to assess receptor activation in HeLa cells.
re s u l t s: We found that bisphenol AF strongly and selectively binds to ERs over ERRγ. 
Furthermore, bisphenol AF receptor-binding activity was three times stronger for ERβ [IC50 
(median inhibitory concentration) = 18.9 nM] than for ERα. When examined using a reporter gene 
assay, bisphenol AF was a full agonist for ERα. In contrast, it was almost completely inactive in 
stimulating the basal constitutive activity of ERβ. Surprisingly, bisphenol AF acted as a distinct and 
strong antagonist against the activity of the endogenous ERβ agonist 17β-estradiol.
co n c l u s i o n: Our results suggest that bisphenol AF could function as an endocrine-disrupting 
chemical by acting as an agonist or antagonist to perturb physiological processes mediated through 
ERα and/or ERβ.
key w o r d s : bisphenol A, bisphenol AF, endocrine disruptor, estrogen receptors, receptor antagonist,   
receptor binding. Environ Health Perspect 118:1267–1272 (2010).  doi:10.1289/ehp.0901819 
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Materials and Methods
Test compounds. We obtained 17β-estradiol 
(CAS no. 50-28-2; 98.9%) from Research 
Biochemicals International (Natick, MA, 
USA), and BPA (CAS no. 80-05-7; purity 
99%) and bisphenol AF (CAS no. 1478-61-1; 
purity 99%) from Tokyo Kasei Kogyo Co. 
Ltd. (Tokyo, Japan). 4-Hydroxytamoxifen 
(4-OHT; CAS no. 68047-06-3; purity 98%) 
and 2,2-bis(p-hydroxyphenyl)-1,1,1-trichloro-
ethane (HPTE) were obtained from Sigma-
Aldrich Inc. (St. Louis, MO, USA). 
Preparation of glutathione S‑transferase–
(GST)‑fused NR ligand‑binding domain 
(LBD) protein. cDNA clones of ERα and ERβ 
were purchased from OriGene Technologies, 
Inc. (Rockville, MD, USA). GST-fused recep-
tor LBDs expressed in Escherichia coli BL21α 
(GST-ERα-LBD, GST-ERβ-LBD, and 
GST-ERRγ-LBD) were purified on an affin-
ity column of glutathione-Sepharose 4B (GE 
Healthcare BioSciences Co., Piscataway, NJ, 
USA) followed by gel filtration on a Sephadex 
G-10 column (15 × 10 mm; GE Healthcare 
BioSciences).
Radioligand binding assays for saturation 
binding. We conducted the saturation binding 
assays for ERα and ERβ essentially as reported 
by Nakai et al. (1999) using tritium-labeled 
ligand [3H]17β-estradiol (5.96 TBq/mmol; 
GE Healthcare UK Ltd., Buckinghamshire, 
UK). Receptor protein GST-ERα-LBD or 
GST-ERβ-LBD (0.3 nM) was incubated with 
increasing concentrations of [3H]17β-estradiol 
(0.1–30 nM) in a final volume of 100 µL 
binding buffer (10 mM Tris, 1 mM EDTA, 
1 mM EGTA, 1 mM sodium vanadate(V), 
0.5 mM phenyl  methyl  sulfonyl fluoride, 
0.2 mM leupeptin, 10% glycerol; pH 7.4). 
Non  specific binding was determined in a par-
allel set of incubations that included 10 µM 
non  radiolabeled 17β-estradiol. After incuba-
tion for 2 hr at 20°C, free radioligand was 
removed by incubation with 0.4% dextran-
coated charcoal (Sigma-Aldrich Inc.) in 
phosphate-buffered saline (PBS; pH 7.4) for 
10 min on ice and then centrifuged for 10 min 
at 15,000 rpm.
We performed the saturation binding assay 
for ERRγ as reported previously (Okada et al. 
(2008) using [3H]BPA (5.05 TBq/mmol; 
Moravek Biochemicals, Brea, CA, USA). 
Specific binding of tritium-labeled ligand was 
calculated by subtracting the non  specific bind-
ing from the total binding. Receptor proteins 
that were expressed and purified were evaluated 
in a saturation binding assay to estimate Kd and 
receptor density (Bmax), and only good-quality 
preparations with appropriate Kd and Bmax were 
used for competitive receptor-binding assays.
Radioligand binding assays for competitive 
binding. Bisphenol AF, BPA, 17β-estradiol, 
and 4-OHT were dissolved in 0.3% DMSO 
in 1% bovine serum albumin (BSA; a blocker 
of non  specific adsorption to the reaction ves-
sels). HPTE was tested as a reference com-
pound that acted as an ERα agonist and an 
ERβ antagonist. These chemi  cals were exam-
ined for their ability to inhibit the binding of 
[3H]17β-estradiol (5 nM in final) to GST-
ERα-LBD (26 ng) and GST-ERβ-LBD 
(26 ng). The reaction mixtures were incubated 
overnight at 4°C, and free radio  ligand was 
removed with 1% dextran-coated charcoal by 
filtration. Radioactivity was determined on a 
liquid scintillation counter (TopCount NXT; 
PerkinElmer Life Sciences Japan, Tokyo, 
Japan). We calculated the half-maximal inhibi-
tory concentrations (IC50) for 17β-estradiol 
from dose–response curves obtained using the 
non  linear analysis program ALLFIT (DeLean 
et al. 1978). Each assay was performed in 
duplicate and repeated at least five times. For 
reconfirmation, we also performed the binding 
assay for ERRγ using [3H]BPA (5 nM final 
concentration) and GST-ERRγ-LBD (26 ng).
Luciferase reporter gene assay. HeLa cells 
were maintained in Eagle’s minimum essen-
tial medium (MEM; Nissui, Tokyo, Japan) 
Figure 1. Chemical structures of (A) BPA, (B) bis‑
phenol AF, (C) 2,2‑bis(p‑hydroxyphenyl)‑1,1,1‑
trichloro  ethane (HPTE), and (D) 17β‑estradiol.
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Figure 2. Radio  ligand receptor‑binding assays of bisphenol AF (BPAF), BPA, and 17β‑estradiol (E2) to 
meas  ure the ability of the compounds to displace [3H]17β‑estradiol in recombinant human ERα (A) and 
ERβ (B). B/B0, sample bound/maximum binding. The representative dose‑dependent binding curves show 
the IC50 value closest to the mean IC50 from at least five independent assays. The IC50 values showed a 
between‑experiment coefficient of variation of 5–12%. 
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Table 1. Receptor‑binding characteristics of BPA and bisphenol AF for ERα, ERβ, and ERRγ.
IC50 (nM)
Compound ERα ERβ ERRγ
17β-estradiol 0.88 ± 0.04 2.17 ± 0.12 NB
4-OHT 2.88 ± 0.15 3.17 ± 0.24 10.3 ± 0.8
BPA 1,030 ± 70 900 ± 70 9.70 ± 0.59
Bisphenol AF 53.4 ± 3.1 18.9 ± 0.84  358 ± 3.1
HPTE 59.1 ± 1.5 18.1 ± 1.9 36.4 ± 4.4
Abbreviations: HPTE, 2,2‑bis(p‑hydroxyphenyl)‑1,1,1‑trichloro  ethane; NB, not bound (no significant receptor binding at 
10 μM, the highest concentration tested).Bisphenol AF: ERα agonist but ERβ antagonist
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in the presence of 10% (vol/vol) fetal bovine 
serum at 37°C. For luciferase assays, HeLa cells 
were seeded at 5 × 105 cells per 6-cm dish for 
24 hr and then transfected with 4 µg reporter 
gene (pGL3/3xERE) and 3 µg of ERα or 
ERβ expression plasmid (pcDNA3/ERs) by 
Lipofectamine Plus reagent (Invitrogen Japan, 
Tokyo, Japan) according to the manufactur-
er’s protocol. Approximately 24 hr after trans-
fection, cells were harvested and plated into 
96-well plates at 5 × 104 cells/well. The cells 
were then treated with varying doses of chemi-
cals diluted with 1% BSA/PBS (vol/vol). After 
24 hr, luciferase activity was meas  ured with the 
appropriate reagent using a Luciferase Assay 
System (Promega, Madison, WI, USA) accord-
ing to the manufacturer’s instructions. Light 
emissions were measured using a Wallace 1420 
ARVOsx multilabel counter (PerkinElmer). 
Cells treated with 1% BSA/PBS were used as 
a vehicle control. Each assay was performed in 
triplicate and repeated at least three times. The 
assay for ERRγ was carried out as previously 
reported (Okada et al. 2008).
To measure the antagonistic activity of 
bisphenol AF for ERβ, we examined four 
concentrations (0.01, 0.1, 1.0, and 10 µM) 
of bisphenol AF for a serial concentration 
of 17β-estradiol (10–12 to 10–5 M in the 
final solution). Also, a serial concentration of 
bisphenol AF (10–12 to 10–5 M in the final 
solution) was assayed in the presence of 10 or 
100 nM concentrations of 17β-estradiol, 
which normally elicit full activation of ERβ.
Results
Strong binding activity of bisphenol AF to 
ERβ receptor. We selected receptor protein 
preparations suitable for the competitive 
receptor-binding assay based on Scatchard 
plot analyses of saturation-binding assays. 
Receptor populations with the appropriate 
dissociation constant (Kd) and receptor den-
sity (Bmax) were used for each radio  ligand 
receptor-binding assay. Because all of the NRs 
are secreted protein preparations, observed 
Bmax values were comparable with those cal-
culated from their molecular weight.
BPA was a very weak ligand for ERα 
(IC50 = 1,030 nM) based on its ability to 
inhibit [3H]17β-estradiol binding (Figure 2A, 
Table 1), as we previously reported (Okada 
et al. 2008). In the present study, we con-
firmed that BPA is also a very weak ligand for 
ERβ (IC50 = 900 nM; Figure 2B, Table 1), 
indicating comparable inter  actions of BPA 
with ERα and ERβ despite the subtle struc-
tural differences between these ERs. In 
contrast, bisphenol AF was 20 times more 
potent than BPA as a ligand for ERα 
(IC50 = 53.4 nM; Figure 2A, Table 1) and was 
approximately 48 times more potent for ERβ 
(IC50 = 18.9 nM; Figure 2B, Table 1). This 
high binding activity for ERβ suggests that 
the binding pocket of ERβ possesses specific 
structural elements that interact much more 
favorably with the CF3 groups of bisphenol 
AF than with the CH3 groups of BPA. We 
also assayed HPTE, an analog of BPA and 
bisphenol AF with the CCl3 group. HPTE 
was almost equi  potent to bisphenol AF in the 
assays for both ERα and ERβ (Table 1), but 
approximately 10 times more potent than bis-
phenol AF for ERRγ.
Receptor‑binding selectivity of bisphenol 
AF and BPA. We used the IC50 values shown 
in Table 1 (from the competitive receptor-
binding assay for nuclear ERα, ERβ, and 
ERRγ) to estimate receptor selectivity ratios 
for BPA and bisphenol AF (Table 2). The 
results indicate that BPA is exclusively selec-
tive for ERRγ, being 90–100 times more 
active for ERRγ than for ERα or ERβ. In 
contrast, bisphenol AF receptor binding is 
much more selective for ERα and ERβ than 
for ERRγ (6.70 times more selective for ERα 
than for ERRγ and 18.94 times more selective 
for ERβ than for ERRγ; Table 2). Bisphenol 
AF binding is also about three times more 
potent for ERβ than for ERα.
Differential effects of bisphenol AF in 
the reporter gene assay. We next examined 
reporter gene activity after bisphenol AF expo-
sure in HeLa cells transiently cotransfected 
with an ERα or ERβ expression plasmid and 
an estrogen-response element (ERE)-luciferase 
reporter plasmid. Bisphenol AF fully activated 
ERα (increasing activity to ~ 7 times the base-
line level) in a dose-dependent manner at con-
centrations of 10–10 to 10–5 M (Figure 3A). 
The half-maximal effective concentration 
(EC50) of bisphenol AF was 58.7 nM.
When we compared potencies for ERα 
activation versus ERα binding to determine 
receptor activation potency [expressed as EC50 
(nM)/IC50 (nM)], we found a clear discrep-
ancy between 17β-estradiol and bisphenol AF. 
As shown in Table 3, we estimated the recep-
tor activation potency for 17β-estradiol to be 
0.085 (0.075 nM/0.88 nM based on values 
from Figure 3A and Table 1, respectively). In 
contrast, the receptor activation potency of 
bisphenol AF [1.099 (58.7 nM/ 53.4 nM)] 
was approximately 13 times greater than that 
Table 2. Receptor‑binding selectivity of BPA and AF for ERα, ERβ, and ERRγ.
Receptor-binding selectivity
Compound ERα vs. ERβ ERα vs. ERRγ ERβ vs. ERRγ Preferred receptor(s)
17β-estradiol 2.47 ERα (ERα)a  (ERβ)a ERα
4-OHT 1.10 ERα 3.58 ERα 3.25 ERβ ERα ~ ERβ
BPA 1.14 ERβ 106.18 ERRγ 92.78 ERRγ  ERRγ
Bisphenol AF 2.83 ERβ 6.70 ERα 18.94 ERβ ERβ
HPTE 3.27 ERβ 1.63 ERRγ 2.01 ERβ ERβ
HPTE, 2,2‑bis(p‑hydroxyphenyl)‑1,1,1‑trichloro  ethane. Data are n‑fold strength of the preferred receptor compared with the 
nonpreferred receptor; for example, ”2.47 ERα” means that 17β‑estradiol binds to ERα 2.47 times more strongly than to ERβ. 
aBecause of inactivity of 17β‑estradiol in ERRγ, 17β‑estradiol is active exclusively in ERα and ERβ. 
Figure 3. Luciferase‑reporter gene assays of bisphenol AF (BPAF), BPA, and 17β‑estradiol (E2) for ERα 
and ERβ using reporter gene (pGL3/3xERE) and either ERα or ERβ expression plasmid (pcDNA3/ERα or 
pcDNA3/ERβ) in HeLa cells. Concentration‑dependent responses of 17β‑estradiol, bisphenol AF, and 
BPA in the luciferase‑reporter gene assay for ERα (A) and ERβ (B). For ERα, bisphenol AF displays full 
activation in a concentration‑dependent manner, whereas for ERβ it displays extremely weak activity. 
17β‑Estradiol exhibits very strong activity, with approximately 4.5 times more activity induced at 10–14 to 
10–5 M than at baseline.
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Table 3. Binding affinities of 17β‑estradiol, BPA, 
and bisphenol AF relative to their potencies for 
stimulating reporter gene activity by ERα and ERβ 
in HeLa cells.
EC50 (nM)/IC50 (nM)
Compound ERα ERβ
17β-estradiol 0.085 (1.0) 0.041 (1.0)
BPA 0.308 (3.6) 0.770 (18.8)
Bisphenol AF 1.099 (12.9) —
Values in the parentheses show the relative value of the 
EC50/IC50 ratio (17β‑estradiol = 1.0).Matsushima et al.
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of 17β-estradiol (Table 3). This means that 
the concentration of 17β-estradiol required 
to stimulate a 50% response is about 13 times 
lower than the concentration required to 
occupy 50% of receptors, whereas the con-
centration of bisphenol AF required to stim-
ulate a 50% response is about the same as 
that required to occupy 50% of receptors. 
This suggests that the receptor conformation 
induced by bisphenol AF is not as condu-
cive to receptor activation as that induced by 
17β-estradiol when measured in HeLa cells.
BPA was an extremely weak activator 
of both ERα (EC50 = 317 nM) and ERβ 
(EC50 = 693 nM) based on the luciferase 
reporter gene assay. The receptor activa-
tion potencies of BPA for ERα (0.308) 
and ERβ (0.770) were 3.6 and 18.8 times 
greater than the receptor activation potencies 
of 17β-estradiol for ERα and ERβ, respec-
tively (Table 3). These suggests that, com-
pared with 17β-estradiol, the concentration of 
BPA required to stimulate a 50% response is 
much higher than the concentration required 
to occupy 50% of receptors. In addition, as 
shown in Figure 3B, BPA exhibited a reduced 
ability to bring about full activation of ERβ 
(3.5 times greater activity relative to baseline 
in response to BPA vs. an increase to 6 times 
the baseline level in response to 17β-estradiol). 
This difference in efficacy indicates that BPA 
does not have the same ability as 17β-estradiol 
to induce activation conformation when meas-
ured in HeLa cells on this promoter.
Antagonist activity of bisphenol AF on 
ERβ. For ERβ, bisphenol AF was almost 
completely inactive, with very little increase in 
activity even at 10 µM, the highest concentra-
tion tested (Figure 3B). Based on the strong 
receptor-binding activity of bisphenol AF for 
ERβ (IC50 = 18.9 nM; Table 1), we expected 
that bisphenol AF would also have a high 
receptor activation potency for ERβ. This 
unexpected inactivity in the reporter gene 
assay suggests that bisphenol AF binding dis-
rupts the ERβ-LBD activation conformation, 
in which the α-helix 12 (H12) of the receptor 
is normally positioned to recruit the coactiva-
tor protein conformation (Brzozowski et al. 
1997; Ruff et al. 2000).
We therefore evaluated the antagonist 
activity of bisphenol AF against 17β-estradiol. 
When we examined 17β-estradiol, an endog-
enous agonist ligand of ERβ, in the presence 
of 0.01, 0.1, 1.0, and 10 µM bisphenol AF, 
its activity (EC50 = 0.075 nM) was gradually 
weakened. As shown in Figure 4A, the dose-
dependent curves of 17β-estradiol shifted to 
the right with increasing concentrations of 
bisphenol AF, indicating that bisphenol AF 
effectively inhibits the interaction between 
17β-estradiol and ERβ. When the results 
of Figure 4A were analyzed using a Schild 
plot, pA2, a meas  ure of affinity of the antago-
nist for receptor, was calculated to be 7.87 
from the dissociation equilibrium constant 
(KB = 1.35 × 10–8 M).
The antagonist activity of bisphenol AF 
for 17β-estradiol/ERβ was further evidenced 
by assays in which we added serial concentra-
tions of bisphenol AF (10–12 to 10–5 M) to 
a solution of 17β-estradiol maintained at a 
constant concentration. When 1 × 10–8 M 
17β-estradiol was treated with bisphenol AF, 
the activity of 17β-estradiol was reduced in 
a dose-dependent manner in response to bis-
phenol AF concentrations ranging from 10–10 
to 10–5 M (Figure 4B). We obtained a similar 
result for 1 × 10–7 M 17β-estradiol. These 
results demonstrate that bisphenol AF can 
antagonize the activity of 17β-estradiol on the 
ERβ receptor.
Discussion
Structural characteristics of bisphenols and 
ERs/ERRγ receptors. The differences in recep-
tor selectivity between bisphenol AF and BPA 
are due to the CH3 ↔ CF3 substitution on 
the bisphenol backbone structure. Bisphenol 
AF is a hexafluoro derivative of BPA with 
the CH3 → CF3 substitution on the back-
bone structure of 2,2-disubstituted propane 
CH3–C–CH3. BPA binds strongly to ERRγ, 
but bisphenol AF binds to ERRγ only weakly; 
we therefore judged that the binding pocket 
of ERRγ-LBD possesses structural elements 
unfavorable for interaction with the trifluoro 
groups. The molecular size of CF3 is almost 
the same as that of CH3, and thus there would 
be no structural repulsion or steric hindrance 
between these groups. However, because the 
CF3 group is very electron rich, the structural 
elements standing face to face with CF3 must 
also be electron rich, resulting in their electro-
static repulsion.
In our previous study (Matsushima et al. 
2007, 2008), we found that the ERRγ bind-
ing sites for BPA CH3 groups were Phe435 
and Met306. Because the aromatic phenyl and 
S–CH3 groups of Phe435 and Met306 are 
electron rich, conditions would be unfavorable 
for binding of bisphenol AF’s electron-rich 
CF3 groups. Corresponding receptor residues 
in ERα are Leu525 and Leu384, respectively. 
Apparently, there would be no electrostatic 
repulsion between the bisphenol AF’s CF3 
groups and the Leu residues. Such a release 
in structural stress must be very favorable for 
receptor activity and the selectivity of bisphe-
nol AF for ERα.
In the present study, we found bisphenol 
AF to be a strong ligand for both ERα and 
ERβ receptors, although it shows a 3 times 
greater preference for ERβ over ERα. A 
much more important finding is that bisphe-
nol AF functions in a different way for ERα 
and ERβ. Bisphenol AF is a full agonist for 
ERα but an antagonist for ERβ. The LBDs of 
ERα and ERβ share a high sequence identity 
(59%) and similar three-dimensional struc-
tures. We observed no obvious differences 
between ERα and ERβ in the ERE transcrip-
tional assays in the presence of 17β-estradiol.
Among the amino acid residues lining   
the binding pockets of ERα and ERβ, 
two residues differ significantly: Leu384 in 
α-helix 5 (H5) of ERα is replaced by Met336 
in ERβ, and Met421 in loop 6–7 of ERα is 
replaced by Ile373 in ERβ. These two resi-
dues are most probably responsible for the 
discriminative affinity and reverse functional 
activity of bisphenol AF for ERα and ERβ. 
Furthermore, because bisphenol AF is an ERβ 
antagonist, the binding of bisphenol AF to 
the ERβ ligand-binding pocket must dam-
age the ERβ-LBD activation conformation, 
in which the α-helix 12 (H12) in LBD is 
Figure 4. Effects of bisphenol AF (BPAF) on the agonist activity of 17β‑estradiol (E2) in the luciferase‑
reporter gene assays for ERβ. (A) Concentration‑dependent luciferase‑reporter activities of 17β‑estradiol 
by fold activation in the presence and absence of bisphenol AF (0.1, 1, or 10 μM); these concentrations of 
bisphenol AF clearly weaken the agonist activity of 17β‑estradiol for ERβ. (B) Concentration‑dependent 
effects of bisphenol AF on the agonist activity of 17β‑estradiol; the agonist activity of 10 nM 17β‑estradiol 
was clearly inhibited by bisphenol AF in a dose‑dependent manner. Bisphenol AF itself sustained 
extremely weak activity for ERβ. In these assays, the reporter gene (pGL3/3xERE) and ERβ expression 
plasmid (pcDNA3/ERβ) were measured in HeLa cells.
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positioned to recruit the coactivator proteins 
conformation (Brzozowski et al. 1997; Ruff 
et al. 2000). Bisphenol AF binding to LBDs 
of ERα and ERβ are being analyzed in light 
of the crystal structures in studies in progress 
in our laboratory.
Bisphenol AF as a candidate of potential   
endocrine disruptor. Bisphenol AF is a potent 
estrogen agonist for ERα and a potent estro-
gen antagonist for ERβ. ERα and ERβ are 
widely distributed throughout the body, 
displaying distinct but overlapping expres-
sion patterns in a variety of tissues. ERα is 
expressed primarily in the uterus, liver, kid-
neys, and heart (Couse and Korach 1999), 
whereas ERβ is expressed primarily in the 
ovaries (Couse and Korach 1999), prostate 
(Couse and Korach 1999), lungs (Kuiper 
et al. 1997), and gastro  intestinal tract and 
bladder (Nilsson et al. 2001). Coexpression 
of both receptors occurs in the mammary 
glands (Pettersson and Gustafsson 2001), 
epididymis (Pau et al. 1998), thyroid (Pau 
et al. 1998), adrenals (Pau et al. 1998), bone 
(Arts et al. 1997; Brandenberger et al. 1997), 
and certain regions of the brain (Couse and 
Korach 1999). [For additional information, 
see Nuclear Receptor Signaling Atlas (2010).] 
17β-Estradiol plays a critical role in many 
physiological processes in both females and 
males. These include normal growth, develop-
ment, and cell-type–specific gene regulation 
in tissues of the reproductive tract, central 
nervous system, and skeleton (Couse and 
Korach 1999; Nilsson et al. 2001; Pettersson 
and Gustafsson 2001). Bisphenol AF is 
a potent binder of ERα and ERβ and thus 
would perturb these physiological processes, 
perhaps providing significant adverse influ-
ences for the central and peripheral systems.
Effects of the bisphenol trihalogenated 
methyl group on receptor actions. Bisphenol 
AF is an agonist for ERα and an antagonist 
for ERβ. Similar results have been reported 
for HPTE, a bisphenolic metabolite of meth-
oxychlor [1,1,1-trichloro-2,2-bis(4-methoxy-
phenyl)ethane]. HPTE behaved as an ERα 
agonist and an ERβ antagonist with estrogen-
responsive promoters in HeLa cells (Gaido 
et al. 1999). We confirmed these results in 
our assay systems as well. HPTE was a strong 
binder of ERα with IC50 = 59.1 nM and 
of ERβ with IC50 = 18.1 nM (Table 1). As 
reported previously by Gaido et al. (1999) and 
Nettles et al. (2004), HPTE acts as a full ago-
nist for ERα but a strong antagonist for ERβ. 
However, bisphenol AF and HPTE differ in 
their receptor preference for ERRγ. HPTE 
was approximately 10 times more potent than 
bisphenol AF for ERRγ binding, although 
both chemicals were most strongly bound 
to ERβ (Tables 1, 2). As an antagonist for 
ERβ, bisphenol AF (pA2 = 7.87) was some-
what stronger than HPTE, the pA2 of which 
was reported to be 7.52 (Gaido et al. 1999). 
However, both bisphenol AF and HPTE are 
significantly potent as ERβ antagonists.
Chemical structures of bisphenol AF and 
HPTE differ, with one of two CF3 groups of 
bisphenol AF replaced by CCl3 in HPTE, and 
the other by H (Figure 1). However, these 
compounds are similar in that both have tri-
halogenated methyl groups that may produce 
different activities for ERα and ERβ via their 
interactions with the ligand-binding pockets 
of each ER, namely, Leu384 in H5 of ERα 
↔ Met336 in ERβ, and Met421 in loop 6–7 
of ERα ↔ Ile373 in ERβ.
Methoxychlor is a chlorinated hydro-
carbon pesticide structurally similar to DDT 
(dichlorodiphenyltrichloroethane) and thus 
is sometimes referred to as dimethoxy or 
methoxy DDT. It had been used to some 
degree as a replacement for DDT to pro-
tect crops, ornamentals, livestock, and pets 
against various insects, because it was believed 
to be metabolized more quickly than DDT, 
thus reducing or preventing bioaccumula-
tion (Kapoor et al. 1970). Methoxychlor is 
utero  tropic in the ovariectomized rat and can 
cause adverse developmental and reproduc-
tive effects in mice and rats (Alm et al. 1996; 
Cummings 1997; Hall et al. 1997). However, 
HPTE is approximately 100 times more 
active at ERs than is methoxychlor. To date, 
the use of methoxychlor has been banned in 
many countries, including the United States, 
Japan, and the European Union. All these 
issues clearly raise concerns that not only 
HPTE but also bisphenol AF may be a poten-
tial endocrine disruptor affecting either ERα 
or ERβ, or both.
Conclusions
BPA binds strongly to ERRγ but very weakly 
to ERα and ERβ. In contrast, bisphenol AF 
binds very weakly to ERRγ but strongly to 
ERα and ERβ. These differences in receptor 
selectivity reflect subtle but distinct structural 
differences resulting from the CH3 ↔ CF3 
substitution on the bisphenol backbone struc-
ture. The trifluoro  methyl group is much 
more electro  negative than the methyl group. 
These results suggest that apparently minor 
structural differences among chemicals and 
NRs may have pronounced effects on bind-
ing affinity and selectivity. Thus, the present 
study emphasizes the crucial importance of 
accurate evaluation of receptor responses to 
understanding interactions between endocrine-
disrupting compounds and diverse human 
NRs. Taken together, these results clearly indi-
cate the importance of examining the degree 
and ways in which bisphenol AF may influence 
the physiological roles of ERα and ERβ. Given 
that bisphenol AF and BPA function as endo-
crine disruptors, these chemicals would work 
differently via different NRs.
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